Molecular remission and non-Hodgkin's lymphoma

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 3, 2002, Pages 549-562

  Darby, Angela J ^a   Johnson, Peter W M ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

bcl 2; Chromosomal translocation; Follicular lymphoma; Immunoglobulin rearrangement; Mantle cell lymphoma; Minimal residual disease; Non Hodgkin's lymphoma; Polymerase chain reaction

Indexed keywords

DIAGNOSTIC PROCEDURE; FOLLICULAR LYMPHOMA; HUMAN; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; REMISSION; REVIEW; BONE MARROW; CANCER CELL; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; EVIDENCE BASED MEDICINE; MORPHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TREATMENT PLANNING; BLOOD; BONE MARROW PURGING; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DRUG MEGADOSE; FOLLOW UP; IMMUNOTHERAPY; LYMPH NODE;

HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM, RESIDUAL; REMISSION INDUCTION;

ALPHA2B INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; GROWTH FACTOR; PREDNISOLONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE; PREDNISONE;

EID: 0036457129     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0216     Document Type: Article

References (49)

1. Hsi ED. Towards a molecular classification of hematolymphoid neoplasms: where are we now? Where are we going? Journal of Histochemistry and Cytochemistry 2001; 49: 1323-1324.
2. Harris NL, Jaffe ES, Diebold J et al. World Health Organisation classification of neoplastic diseases of the haemopoietic and lymphoid tissues. Journal of Clinical Oncology 1999; 17: 3835-3849.
3. Magrath IT. Non-Hodgkin's lymphomas. Encyclopaedia of Life Sciences 2002; www.els.net 1-12.
4. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukaemia. New England Journal of Medicine 2001; 344: 1031-1037.
5. Yunis JJ, Oken MM, Kaplen ME et al. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. New England Journal of Medicine 1982; 307: 1231-1236.
6. Tsujimoto Y, Finger LR, Yunis J et al. Cloning of the chromosome breakpoint of neoplastic B-cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097-1099.
7. Lopez-Guillermo A, Cabanillas F, McDonnell TI et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 1999; 93: 3081-3087.
8. Tsujimoto Y, Gorham J, Cossman J et al. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985; 229: 1390-1393.
9. Ngan BY, Nourse J & Cleary ML. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 1989; 73: 1759-1762.
10. Cotter F, Price C, Zucca E et al. Direct sequence analysis ofthe 14q+ and 18q- chromosome junctions in follicular lymphoma. Blood 1990; 76: 131-135.
11. Johnson PWM, Swinbank K, Maclennan S et al. Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. Annals of Oncology 1999; 10: 1349-1354.
12. Limpens J, de Jong D, van Krieken JH et al. Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 1991; 6: 2271-2276.
13. Aster JC, Kobayashi Y, Shiota M et al. Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients. American Journal of Pathology 1992; 141: 291-299.
14. Dolken G, Illerhaus G, Hirt C et al. BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with non-malignant diseases. Journal of Clinical Oncology 1996; 14: 1333-1344.
15. Summers KE, Goff LK, Wilson AG et al. Incidence and frequency of Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. Journal of Clinical Oncology 2001; 19: 420-424.
16. Yunis JJ, Mayer MG, Arnesen MA et al. Bcl-2 and other genomic alterations in the prognosis of large cell lym phoma. New England Journal of Medicine 1989; 320: 1047-1054.
17. Tilly H & Rosso A. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 1994; 84: 1043-1049.
18. Johnson A, Brun A, Dictor M et al. Incidence and prognostic significance of t(14;18) translocation in follicle centre cell lymphoma of low and high grade: a report from southern Sweden. Annals of Oncology 1995; 6: 789-794.
19. Mandigers CM, Meijerink JP, Mensink EJ et al. Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood 2001; 98: 940-944.
20. Bertoni F, Bosshard G, Roggero E et al. Clinical relevance of bcl-2(MBR)/J(H) rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma. British Journal of Cancer 1997; 76: 36-39.
21. Apostoliclis J, Foran JM, Johnson PWM et al. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. Journal of Clinical Oncology 1999; 17: 216-221.
22. Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'adulte (GELA). Blood 1996; 87: 265-272.
23. Hill ME, MacLennan KA, Cunningham D et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996; 88: 1046-1051.
24. Gribben JG, Freedman A, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275-3280.
25. Gribben JG, Neuberg D, Barber M et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predicative for relapse than detection in bone marrow. Blood 1994; 83: 3800-3807.
26. Yuan R, Dowling P, Zucca E et al. Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: concordant results of peripheral blood and bone marrow analysis at diagnosis. British Journal of Cancer 1993; 67: 922-925.
27. Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998; 98: 2955-2960.
28. Price CG, Meerabux J, Murtagh S et al. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. Journal of Clinical Oncology 1991; 9: 1527-1532.
29. Lambrechts AC, Hupkes PE, Dorssers LCJ et al. Clinical significance of t(14;18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission. Journal of Clinical Oncology 1994; 12: 1541-1546.
30. Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Annals of Oncology 2000; 11: 137-140.
31. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone-marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325-3333.
32. Ratanatharathom V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
33. Macintyre EA, Belanger C, Debert C et al. Detection of clonal CD34+ 19+ progenitors in bone marrow of BCL2/IgH-positive follicular lymphoma patients. Blood 1995; 86: 4691-4698.
34. Schouten HC, Kvaloy S, Sycles M et al. The CUP trial: a randomised study analysing the efficacy of high dose ther-apy and purging in low-grade non-Hodgkin's lymphoma (NHL). Annals of Oncology 2000; 11 (supplement I): 91-94.
35. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. New England Journal of Medicine 1991; 325: 1525-1533.
36. Johnson PW, Price CG, Smith T et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. Journal of Clinical Oncology 1994; 12: 798-805.
37. Andersen NS, Donovan JW, Borus JS et al. Failure of immunological purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90: 4212-4221.
38. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864-869.
39. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-3457.
40. Hardingham JE, Kotasek D, Sage RE et al. Significance of molecular marker positive cells after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Journal of Clinical Oncology 1995; 13: 1073-1079.
41. Freedman AS, Gribben JG & Nadler LM. High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. Leukaemia & Lymphoma 1998; 28: 219-230.
42. Moos M, Schulz R, Martin S et al. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukaemia 1998; 12: 1971-1976.
43. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-106.
44. Foran JM, Gupta RK, Cunningham D et al. A UK multicentre phase II study of Rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. British Journal of Haematology 2000; 109: 81-88.
45. Czuczman MS, Grillo-Lopez AJ, McLaughlin P et al. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Annals of Oncology 2001; 12: 109-114.
46. Howard OM, Gribben JG, Neuberg D et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. Journal of Clinical Oncology 2002; 20: 1288-1294.
47. Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856-862.
48. Kaminski MS, Gribbin T, Ester J et al. 1-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions. Proceedings of ASCO 1998; 17: 2a.
49. Darby AJ, Lanham SA, Johnson PWM. International multicenter study of variability of detection of the Bcl-2/IgW translocation using quantitative PCR. Annals of Oncology 2002; 13: 51a.